|
Apr 1
|
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
|
|
Apr 1
|
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
|
|
Apr 1
|
Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins
|
|
Apr 1
|
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
|
|
Mar 31
|
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
|
|
Mar 31
|
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
|
|
Mar 31
|
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
|
|
Mar 31
|
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
|
|
Mar 31
|
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
|
|
Mar 28
|
Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds?
|
|
Mar 27
|
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
|
|
Mar 27
|
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
|
|
Mar 26
|
AstraZeneca says new results reinforce Tagrisso as backbone therapy
|
|
Mar 26
|
Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know
|
|
Mar 25
|
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
|
|
Mar 14
|
AstraZeneca Stock Scores RS Rating Upgrade
|
|
Mar 14
|
INOVIO’s Covid-19 dMAb maintains in-vivo detection in 100% participants
|
|
Mar 14
|
AstraZeneca director says AI must be a “thought partner” in drug discovery
|
|
Mar 14
|
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
|
|
Mar 13
|
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
|